Literature DB >> 33087877

Vitamin D levels and busulphan kinetics in patients undergoing hematopoietic stem cell transplantation, a multicenter study.

Ahmed El-Serafi1,2, Rui He3,4, Wenyi Zheng3,4, Fadwa Benkossou3,4, Sandra Oerther3,5, Ying Zhao3,4, Karin Mellgren6, Britt Gustafsson7, Carsten Heilmann8, Jukka Kanerva9, Kourosh Lotfi10,11, Jacek Toporski12, Mikael Sundin13,14, Martin Höglund15, Jonas Mattsson16,17,18, Ibrahim El-Serafi1,18,19, Moustapha Hassan20,21.   

Abstract

Vitamin D (Vit-D), an essential nutrient, interacts with different drugs including chemotherapeutic agents like busulphan, an alkylating agent used for conditioning prior to stem cell transplantation. The correlation between Vit-D plasma levels and busulphan clearance was investigated in an uncontrolled prospective study in patients and mice. Plasma 25(OH)D levels were measured and busulphan pharmacokinetics calculated in 81 patients. Adults received oral busulphan (n = 34) while children received busulphan orally (n = 19) or intravenously (n = 28). Patients received no Vit-D supplementation. To confirm our findings, pharmacokinetics after a single dose of busulphan (oral or intravenous) were evaluated in two groups of mice (n = 60) receiving high or standard-level Vit-D supplementation. Both busulphan clearance (P < 0.0001) and 25(OH)D levels (P = 0.0004) were significantly higher in adults compared to children. A significant negative correlation (P = 0.041) was found between busulphan clearance and 25(OH)D levels in children treated orally. No such correlation was observed in adults or in children receiving intravenous busulphan. In addition, no significant effect of Vit-D levels on busulphan pharmacokinetics in mice regardless of the administration route. In conclusion, 25(OH)D can affect oral busulphan pharmacokinetics in children and its level should be considered when personalizing oral busulphan treatment. Further studies are warranted to confirm the underlying mechanisms.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33087877     DOI: 10.1038/s41409-020-01091-y

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  55 in total

Review 1.  Personalizing Busulfan-Based Conditioning: Considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines Committee.

Authors:  Jeanne Palmer; Jeannine S McCune; Miguel-Angel Perales; David Marks; Joseph Bubalo; Mohamad Mohty; John R Wingard; Angelo Paci; Moustapha Hassan; Christopher Bredeson; Joseph Pidala; Nina Shah; Paul Shaughnessy; Navneet Majhail; Jeff Schriber; Bipin N Savani; Paul A Carpenter
Journal:  Biol Blood Marrow Transplant       Date:  2016-07-29       Impact factor: 5.742

2.  Itraconazole can increase systemic exposure to busulfan in patients given bone marrow transplantation. GITMO (Gruppo Italiano Trapianto di Midollo Osseo).

Authors:  I Buggia; M Zecca; E P Alessandrino; F Locatelli; G Rosti; A Bosi; A Pession; B Rotoli; I Majolino; A Dallorso; M B Regazzi
Journal:  Anticancer Res       Date:  1996 Jul-Aug       Impact factor: 2.480

3.  Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia.

Authors:  Borje S Andersson; Peter F Thall; Timothy Madden; Daniel Couriel; Xuemei Wang; Hai T Tran; Paolo Anderlini; Marcos de Lima; James Gajewski; Richard E Champlin
Journal:  Biol Blood Marrow Transplant       Date:  2002       Impact factor: 5.742

4.  Ketobemidone may alter busulfan pharmacokinetics during high-dose therapy.

Authors:  M Hassan; J O Svensson; C Nilsson; P Hentschke; A Al-Shurbaji; J Aschan; P Ljungman; O Ringdén
Journal:  Ther Drug Monit       Date:  2000-08       Impact factor: 3.681

Review 5.  Vitamin D metabolism, mechanism of action, and clinical applications.

Authors:  Daniel D Bikle
Journal:  Chem Biol       Date:  2014-02-13

6.  Effect of genetic variants GSTA1 and CYP39A1 and age on busulfan clearance in pediatric patients undergoing hematopoietic stem cell transplantation.

Authors:  Marloes H ten Brink; Tom van Bavel; Jesse J Swen; Tahar van der Straaten; Robbert G M Bredius; Arjan C Lankester; Juliëtte Zwaveling; Henk-Jan Guchelaar
Journal:  Pharmacogenomics       Date:  2013-11       Impact factor: 2.533

7.  Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens.

Authors:  L B Grochow
Journal:  Semin Oncol       Date:  1993-08       Impact factor: 4.929

Review 8.  Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation.

Authors:  J T Slattery; L J Risler
Journal:  Ther Drug Monit       Date:  1998-10       Impact factor: 3.681

9.  Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103).

Authors:  Jan H Beumer; Kouros Owzar; Lionel D Lewis; Chen Jiang; Julianne L Holleran; Susan M Christner; William Blum; Steven Devine; Jonathan E Kolitz; Charles Linker; Ravi Vij; Edwin P Alyea; Richard A Larson; Mark J Ratain; Merrill J Egorin
Journal:  Cancer Chemother Pharmacol       Date:  2014-08-28       Impact factor: 3.333

10.  Flavin-containing monooxygenase 3 (FMO3) role in busulphan metabolic pathway.

Authors:  Ibrahim El-Serafi; Ylva Terelius; Manuchehr Abedi-Valugerdi; Seán Naughton; Maryam Saghafian; Ali Moshfegh; Jonas Mattsson; Zuzana Potácová; Moustapha Hassan
Journal:  PLoS One       Date:  2017-11-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.